Diaceutics (LON:DXRX) Stock Price Up 0.8% - Still a Buy?

Diaceutics PLC (LON:DXRX - Get Free Report) rose 0.8% during trading on Friday . The company traded as high as GBX 120 ($1.65) and last traded at GBX 119.48 ($1.64). Approximately 72,885 shares were traded during trading, a decline of 43% from the average daily volume of 127,715 shares. The stock had previously closed at GBX 118.50 ($1.63).

Diaceutics Stock Up 0.8%

The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. The firm has a market cap of £100.83 million, a price-to-earnings ratio of -35.44 and a beta of 0.58. The stock's 50 day moving average is GBX 125.28 and its 200 day moving average is GBX 128.97.

Diaceutics (LON:DXRX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported GBX (2.02) (($0.03)) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. Analysts forecast that Diaceutics PLC will post 1.0107919 EPS for the current year.

Insiders Place Their Bets

In related news, insider Peter Keeling sold 500,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of GBX 126 ($1.73), for a total value of £630,000 ($864,553.31). 34.30% of the stock is currently owned by company insiders.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.